Semax: Side Effects & Safety
Part of the Semax Complete Guide
Research Peptides
Advertiser link — we may earn a commission at no extra cost to you.
Semax Safety: What the Russian & Western Literature Shows
Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia in the 1980s as a stable analog of adrenocorticotropic hormone fragment ACTH(4-10). Despite its ACTH origin, Semax was specifically engineered to remove the corticotropic effects — it does not activate the HPA axis or stimulate cortisol release, which is the most clinically relevant safety fact about this molecule.[1]
It is approved in Russia (Innovative Pharma's "Semax" 0.1% and 1% nasal sprays) for ischemic stroke, transient ischemic attack, and cognitive disorders. It is not FDA-approved in the United States, but Semax-related bulk drug substances are on the agenda for the July 23–24, 2026 FDA Pharmacy Compounding Advisory Committee meeting (docket FDA-2025-N-6895). If the committee recommends inclusion on the 503A bulks list, Semax could become legally compoundable by licensed US pharmacies with a valid prescription — a major change to current Category 2 research-only status.
The published safety data comes primarily from Russian clinical trials in stroke, depression, and cognitive disorders — generally short-duration (10–14 days) with thousands of patients across studies. Long-term continuous-dose safety data in healthy adults is limited.
Reported Side Effects by Frequency
| Effect | Frequency | Route | Notes |
|---|---|---|---|
| Mild nasal irritation / dryness | Common (~5–10%) | Intranasal | Resolves within minutes; adapts over first week |
| Transient nasal taste / drainage | Common | Intranasal | Normal physiological response to nasal spray |
| Sleep disturbance if dosed late | Uncommon (~2–5%) | Both | Move dose to morning/early afternoon |
| Mild headache (initial week) | Uncommon | Both | Usually self-resolves; reduce dose if persistent |
| Increased focus → overstimulation in sensitive individuals | Uncommon | Both | Reduce dose or frequency |
| Mild GI upset | Uncommon | Both | Resolves without intervention |
| Injection site reaction | Common at site | Subcutaneous only | Mild redness; rotate sites |
| Allergic reaction | Rare (<1%) | Both | Discontinue and seek evaluation |
Russian clinical trials reported no serious adverse events at therapeutic doses. The most consistently reported pattern is excellent tolerability — Semax was specifically designed to remove the hormonal effects of its ACTH parent peptide.
No HPA-Axis or Cortisol Effects
Semax is derived from ACTH(4-10), but the heptapeptide sequence used in Semax is structurally modified (Pro-Gly-Pro tail added) so it does not bind melanocortin receptors that mediate cortisol release. Multiple Russian studies have measured plasma cortisol before and after Semax administration in healthy volunteers and stroke patients and found no significant elevation.[1]
This separates Semax from the corticotropic effects of ACTH and means it can be used without the cortisol-driven side effects (weight gain, immune suppression, glucose intolerance) of true corticotropic peptides.
Contraindications & Drug Interactions
- Pregnancy and breastfeeding: no controlled data; Semax is contraindicated.
- Children under 7: some Russian pediatric protocols exist for cognitive disorders but require pediatric neurology supervision.
- Acute psychiatric conditions: caution in mania, acute psychosis, or severe anxiety — the activating effect can amplify symptoms.
- Severe convulsive disorders: Semax is not contraindicated but should be initiated only with neurology oversight.
- Drug interactions: no well-characterized CYP450 interactions. Theoretical additive effect with stimulants (modafinil, caffeine, ADHD medications) and with MAOIs (via dopamine/serotonin modulation). Space dosing from sedative hypnotics by several hours.
What to Do If You Experience Side Effects
- Nasal irritation: reduce concentration or switch to subcutaneous. Saline rinse before dosing can help.
- Sleep disruption: shift all doses to before 14:00; reduce total daily dose.
- Headache: hydrate; reduce dose by 50% for 2–3 days then retry standard dose.
- Overstimulation / anxiety: stop for 3–5 days. Restart at half-dose if you still want to use it; some users do better on alternating-day protocols.
- Allergic reaction: discontinue immediately and seek medical evaluation.
See the Semax complete guide, dosage protocols, and benefits and research.